GAOMA Therapeutics is a pharmaceutical company developing a unique portfolio of novel lipid active ingredients and vectors. With its proprietary drug candidates, GAOMA is committed to address unmet medical needs in neurological and inflammatory disorders.
GAOMA has a particular expertise in the field of epilepsy and intends to explore the efficacy of its molecules in other indications such as Alzheimer’s Disease.
The company was founded in 2019, based on the research outcomes of the Translational and Integrative Group in Epilepsy Research (TIGER), which is part of the Lyon Neuroscience Research Center (CRNL). GAOMA Therapeutics is headquartered in the Lyon area, within the European Epilepsy Institute (IDEE).